Up-to-the-minute newsfeed of the latest medical and scientific journal articles and abstracts related to pancreatic cancer.
A phase I study combining nivolumab (Opdivo) with nab-paclitaxel (Abraxane) and gemcitabine demonstrated that the combination is feasible and the antitumor activity of this regimen appears to be encouraging for…
“Both of these modalities enable us to overcome limitations that we have had in the past to deliver definitive curative doses of radiation,” he said. Read more . . .
According to O'Reilly, there is compelling science and biology behind using immunotherapy combinations in pancreatic cancer, since single-agent checkpoint inhibitors are insufficient. Watch here . . .
Read more . . .
The study, which was published in Nature Communications, Read more . . .
Watch video here . . .